시장보고서
상품코드
1429327

세계의 안티센스와 RNAi 치료제 시장 보고서(2024년)

Antisense & RNAi Therapeutics Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

안티센스와 RNAi 치료제 시장 규모는 향후 수년간 급속히 성장할 것으로 예상되고 있습니다. 2028년에는 12.3%의 연간 복합 성장률(CAGR)로 28억 1,000만 달러로 성장할 것으로 예상됩니다. 안티센스 및 RNAi 치료제의 예상 성장은 의료 접근성 개선, 암 발병률 증가, 신종 코로나바이러스 감염증(COVID-19)으로 인한 수요 증가 등의 요인에 의해 주도되고 있습니다. 주요 동향으로는 희귀질환 RNA 치료제 중심의 연구개발, 나노입자 활용, 안티센스 및 RNAi 치료제 혁신, 수익성 향상을 위한 제품 혁신을 위한 협업 등을 꼽을 수 있습니다.

관상동맥질환, 신경퇴행성 질환, 감염성 질환의 발생률이 증가함에 따라 안티센스 및 RNAi 치료제 시장 수요가 증가할 것으로 예상됩니다. RNAi 및 안티센스 올리고뉴클레오티드와 같은 이러한 유전자 억제 방법론은 결함이 있는 유전자를 교정하여 다양한 신경 퇴행성 질환을 치료하는 데 활용되고 있습니다. 특히 알츠하이머병과 파킨슨병은 전 세계 많은 사람들에게 영향을 미치는 가장 광범위한 신경 퇴행성 질환 중 하나입니다. 2023년 1월 기준 미국에서만 약 620만 명의 알츠하이머병 환자와 약 50만 명의 파킨슨병 환자가 진단을 받았습니다. 결과적으로 이러한 신경퇴행성 질환 및 감염성 질환의 유병률 증가는 안티센스 및 RNAi 치료제 시장의 성장을 가속할 것으로 예상됩니다.

만성질환의 유병률이 급증하면서 안티센스 및 RNAi 치료제에 대한 수요가 증가할 것으로 예상됩니다. 만성질환에는 결정적인 치료법이 없는 심혈관질환, 종양질환 등 장기적으로 지속되는 건강상태가 포함됩니다. 안티센스 및 RNAi 치료제는 병인과 관련된 유전자 또는 분자 경로를 특이적으로 표적화하여 다양한 심혈관 질환을 치료할 수 있을 것으로 기대되고 있습니다. 세계보건기구(WHO)의 World Heart Report 2023에 따르면 2021년 약 2,050만 명이 심혈관 질환으로 사망했으며, 이는 그 해 전 세계 사망자의 거의 3분의 1을 차지합니다. 따라서 만성질환의 유병률 증가는 안티센스 및 RNAi 치료제 시장의 성장을 가속할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계의 안티센스와 RNAi 치료제 시장 촉진요인과 억제요인
    • 시장 촉진요인
    • 시장 억제요인
  • 세계의 안티센스와 RNAi 치료제 시장 규모 실적과 성장, 2018-2023년
  • 세계의 안티센스와 RNAi 치료제 시장 규모와 성장 예측, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 안티센스와 RNAi 치료제 시장, 기술별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • RNAi
  • 안티센스 RNA
  • 세계의 안티센스와 RNAi 치료제 시장, 투여 경로별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 정맥주사
  • 피내 주사
  • 기타
  • 세계의 안티센스와 RNAi 치료제 시장, 적응증별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 종양학
  • 심혈관질환(CVD)
  • 호흡기질환
  • 신경학적 장애
  • 감염증
  • 기타

제7장 지역과 국가 분석

  • 세계의 안티센스와 RNAi 치료제 시장, 지역별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 안티센스와 RNAi 치료제 시장, 국가별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 안티센스와 RNAi 치료제 시장의 경쟁 구도
  • 안티센스와 RNAi 치료제 시장의 기업 개요
    • Biogen Inc.
    • Ionis Pharmaceuticals Inc.
    • Alnylam Pharmaceuticals Inc.
    • Arrowhead Pharmaceuticals Inc.
    • Moderna Inc.

제31장 기타 대기업과 혁신적 기업

  • Sanofi SA
  • Dicerna Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Acuitas Therapeutics
  • Adhera Therapeutics Inc.
  • EdiGene Inc.
  • Sirnaomics Inc.
  • Suzhou Ribo Life Science Co. Ltd
  • Biocon Limited
  • Quark Pharmaceuticals
  • GlaxoSmithKline Plc
  • Shanghai Junshi Biosciences Co. Ltd.
  • AstraZeneca
  • Benitec Biopharma Limited
  • Silence Therapeutics

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 합병과 인수

제35장 향후 전망과 잠재성 분석

제36장 부록

KSA 24.03.08

Antisense therapy involves the targeted and sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to the sequence-specific degradation of single-stranded target RNAs.

The primary technologies in antisense and RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA, which plays a role in resisting both endogenous parasitic and exogenous pathogenic nucleic acids, and it regulates the expression of protein-coding genes. Various routes of administration for these therapies include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other methods. These therapies are used for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and others.

The antisense & RNAi therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period of antisense and RNAi therapeutics can be attributed to increased funding, advancements in technologies, rising healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets.

The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The anticipated growth in antisense and RNAi therapeutics is driven by factors such as improved healthcare access, a growing cancer prevalence, and increased demand due to COVID-19. Key trends include research and development focus on RNA therapeutics for orphan diseases, utilization of nanoparticles, innovation in antisense and RNAi therapeutics, and collaboration for product innovation to boost revenues.

The escalating incidence of coronary artery diseases, neurodegenerative disorders, and infectious ailments is anticipated to fuel the demand for the antisense & RNAi therapeutics market. These gene suppression methodologies, such as RNA interference and antisense oligonucleotides, are utilized in treating various neurodegenerative ailments by rectifying defective genes. Notably, Alzheimer's disease and Parkinson's disease are among the most widespread neurodegenerative conditions affecting a substantial global population. The USA alone records approximately 6.2 million cases of Alzheimer's disease and about 500,000 diagnoses of Parkinson's disease as of January 2023. Consequently, the increasing prevalence of these neurodegenerative disorders and infectious illnesses is expected to propel the growth of the antisense & RNAi therapeutics market.

The surge in chronic diseases' prevalence is foreseen to drive the demand for antisense & RNAi therapeutics. Chronic diseases encompass long-term health conditions such as cardiovascular ailments, oncological disorders, among others, which lack definitive cures. Antisense and RNA interference (RNAi) therapeutics exhibit promise in treating various cardiovascular diseases by specifically targeting genes or molecular pathways associated with their pathogenesis. As outlined in the World Heart Report 2023 by the World Health Organization (WHO), approximately 20.5 million individuals succumbed to cardiovascular conditions in 2021, constituting nearly one-third of global deaths for that year. Hence, the growing prevalence of chronic diseases is expected to propel the expansion of the antisense & RNAi therapeutics market.

Major companies in the antisense & RNAi therapeutics sector are employing strategic collaborations and partnerships as key initiatives to maintain their positions in an increasingly competitive market landscape. These partnerships involve joint efforts between two or more companies aiming to achieve shared objectives. For instance, in January 2023, Orbit Discovery Limited, a US-based company specializing in peptide discovery services, teamed up with SanegeneBio Inc., a UK-based firm focused on developing innovative RNAi-based medicines. This collaboration aims to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown. The partnership involves hit identification and cell-based internalization studies, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Sanegene gains the opportunity to further develop potential hits derived from the screening activities for advanced RNAi therapeutics.

Major players in the antisense & RNAi therapeutics market are fostering partnerships to forge new relationships aimed at jointly creating innovative products. These strategic collaborations represent cooperative alliances between organizations, pooling their strengths or resources toward common goals. For example, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical giant, and Wave Life Sciences, a US-based company specializing in genetic medicines, announced a collaboration to develop oligonucleotide therapeutics targeting novel genetic markers. By integrating GSK's genetic expertise with Wave's PRISM platform, the collaboration aims to advance up to eight preclinical programs. Additionally, GSK secures an exclusive global license for Wave's WVE-006, a potential RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, leveraging innovative chemistry to optimize the properties of therapeutic oligonucleotides.

In December 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, revealed a strategic partnership with Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company specializing in the discovery and development of RNA-based therapeutics and drugs. As part of this collaboration, the two companies will jointly develop and commercialize Eplontersen in the United States, while AstraZeneca will handle development and commercialization in all other regions outside of Latin America.

Major companies operating in the antisense & rnai therapeutics market report are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd., Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline PLC, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc., Calando Pharmaceuticals, Enzon Pharmaceuticals Inc., Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilac ve SaglIk Urunleri A.S., Egypt Otsuka Pharmaceutical

North America was the largest region in the antisense & RNAi therapeutics market in 2023. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antisense & rnai therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antisense & RNAi Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antisense & RNAi therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antisense & RNAi therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antisense & RNAi therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Technology: RNA Interference; Antisense RNA
  • 2) By Route of Administration: Intravenous Injections; Intra-dermal Injections; Other Delivery Methods
  • 3) By Indication: Oncology; Cardiovascular Diseases (CVDs); Respiratory Disorders; Neurological Disorders; Infectious Diseases; Other Indications
  • Companies Mentioned: Biogen Inc.; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Moderna Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antisense & RNAi Therapeutics Market Characteristics

3. Antisense & RNAi Therapeutics Market Trends And Strategies

4. Antisense & RNAi Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Antisense & RNAi Therapeutics Market Size and Growth

  • 5.1. Global Antisense & RNAi Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antisense & RNAi Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antisense & RNAi Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antisense & RNAi Therapeutics Market Segmentation

  • 6.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • RNA Interference
  • Antisense RNA
  • 6.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intravenous Injections
  • Intra-dermal Injections
  • Other Delivery Methods
  • 6.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Other Indications

7. Antisense & RNAi Therapeutics Market Regional And Country Analysis

  • 7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antisense & RNAi Therapeutics Market

  • 8.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antisense & RNAi Therapeutics Market

  • 9.1. China Antisense & RNAi Therapeutics Market Overview
  • 9.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antisense & RNAi Therapeutics Market

  • 10.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antisense & RNAi Therapeutics Market

  • 11.1. Japan Antisense & RNAi Therapeutics Market Overview
  • 11.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antisense & RNAi Therapeutics Market

  • 12.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antisense & RNAi Therapeutics Market

  • 13.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antisense & RNAi Therapeutics Market

  • 14.1. South Korea Antisense & RNAi Therapeutics Market Overview
  • 14.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antisense & RNAi Therapeutics Market

  • 15.1. Western Europe Antisense & RNAi Therapeutics Market Overview
  • 15.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antisense & RNAi Therapeutics Market

  • 16.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antisense & RNAi Therapeutics Market

  • 17.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antisense & RNAi Therapeutics Market

  • 18.1. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antisense & RNAi Therapeutics Market

  • 19.1. Italy Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antisense & RNAi Therapeutics Market

  • 20.1. Spain Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antisense & RNAi Therapeutics Market

  • 21.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
  • 21.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antisense & RNAi Therapeutics Market

  • 22.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antisense & RNAi Therapeutics Market

  • 23.1. North America Antisense & RNAi Therapeutics Market Overview
  • 23.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antisense & RNAi Therapeutics Market

  • 24.1. USA Antisense & RNAi Therapeutics Market Overview
  • 24.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antisense & RNAi Therapeutics Market

  • 25.1. Canada Antisense & RNAi Therapeutics Market Overview
  • 25.2. Canada Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antisense & RNAi Therapeutics Market

  • 26.1. South America Antisense & RNAi Therapeutics Market Overview
  • 26.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antisense & RNAi Therapeutics Market

  • 27.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antisense & RNAi Therapeutics Market

  • 28.1. Middle East Antisense & RNAi Therapeutics Market Overview
  • 28.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antisense & RNAi Therapeutics Market

  • 29.1. Africa Antisense & RNAi Therapeutics Market Overview
  • 29.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Antisense & RNAi Therapeutics Market Competitive Landscape
  • 30.2. Antisense & RNAi Therapeutics Market Company Profiles
    • 30.2.1. Biogen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Ionis Pharmaceuticals Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Alnylam Pharmaceuticals Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Arrowhead Pharmaceuticals Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Moderna Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Antisense & RNAi Therapeutics Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Dicerna Pharmaceuticals Inc.
  • 31.3. Arbutus Biopharma Corporation
  • 31.4. Acuitas Therapeutics
  • 31.5. Adhera Therapeutics Inc.
  • 31.6. EdiGene Inc.
  • 31.7. Sirnaomics Inc.
  • 31.8. Suzhou Ribo Life Science Co. Ltd
  • 31.9. Biocon Limited
  • 31.10. Quark Pharmaceuticals
  • 31.11. GlaxoSmithKline Plc
  • 31.12. Shanghai Junshi Biosciences Co. Ltd.
  • 31.13. AstraZeneca
  • 31.14. Benitec Biopharma Limited
  • 31.15. Silence Therapeutics

32. Global Antisense & RNAi Therapeutics Market Competitive Benchmarking

33. Global Antisense & RNAi Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

35. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Antisense & RNAi Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Antisense & RNAi Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Antisense & RNAi Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제